DPP4 and COVID-19: To the best of our knowledge, we are the first to hypothesize that DPP-4 inhibitors might emerge as a valuable asset in the alleviation of COVID-19 long-term repercussions following patients’ recovery, given their favorable effects in protection and tissue regeneration.